Precision Approach to PPI Therapy in Gastroesophageal reflux disease
This Study is
No Longer Enrolling
Over the past 25 years, RALS has been increasingly, and often incorrectly, diagnosed and has emerged as a point of controversy and confusion. Despite the limitations of current diagnostic tests and therapeutic strategies, recent advances in gastoresophageal reflux disease offer tremendous potential for RALS diagnosis and treatment. Newer diagnostic tools are able to assess physiologic properties of RALS. Thus, this study will address three crucial gaps impacting the clinical approach to RALS: 1) Paucity of diagnostic tests that predict clinically relevant outcomes, 2) undefined clinical role of UES augmentation, and 3) deficiency or cost-effective and personalized approaches.
MoreAdult
18 years and older Willing to be on PPI >8 weeks if symptoms
Subjects diagnosed with reflux associated laryngeal symptoms
Outcomes Research
University of Colorado Hospital
Protocol Number: 18-0205
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers